{"entity":{"id":"nct04712097","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","aka":["Celestimo"],"tldr":"A phase 3 trial of Mosunetuzumab, Lenalidomide, Rituximab in follicular lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT04712097 by Hoffmann-La Roche, with 478 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2026-06-03. Interventions recorded: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab. Conditions listed: Relapsed or Refractory Follicular Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04712097","url":"https://clinicaltrials.gov/study/NCT04712097"}],"tags":["ctgov-ingest"],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":["monoclonal-antibody","protac-degrader","t-cell-engager"],"targets":[],"drugs":["mosunetuzumab","lenalidomide","rituximab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04712097","phase":"3","setting":"Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy","sponsor":"Hoffmann-La Roche","started":"2021-10-27","startedType":"actual","enrolled":478,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04712097/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}